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Abstract
Background: Due to their rising incidence and progressive geographical spread, infections with mosquito-borne
viruses, such as dengue (DENV), chikungunya and zika virus, have developed into major public health challenges.
Since all of these viruses may cause similar symptoms and can occur in concurrent epidemics, tools for their
differential diagnosis and epidemiological monitoring are of urgent need.
Results: Here we report the application of a novel strategy to rapidly generate monoclonal antibodies (mAbs)
against native viral antigens, exemplified for the DENV nonstructural glycoprotein 1 (NS1). The described system is
based on the immunization of mice with transfected mammalian cells expressing the target antigens in multiple
displays on their cell surface and thereby presenting them efficiently to the host immune system in their native
conformation. By applying this cell-based approach to the DENV NS1 protein of serotypes 1 (D1NS1) and 4 (D4NS1),
we were able to rapidly generate panels of DENV NS1 serotype cross-reactive, as well as D1NS1- and D4NS1
serotype-specific mAbs. Our data show that the generated mAbs were capable of recognizing the endogenous
NS1 protein in DENV-containing biological samples.
Conclusion: The use of this novel immunization strategy, allows for a fast and efficient generation of hybridoma
cell lines, producing mAbs against native viral antigens. Envisaged applications of the mAbs include the development of
test platforms enabling a differentiation of the DENV serotypes and high resolution immunotyping for epidemiological
studies.
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Background
The past decades have witnessed a dramatic upsurge or
emergence of arboviral diseases [1], including dengue
[2, 3], chikungunya [4], and zika [5–7]. Since transmission
of these viruses occurs through Aedes aegypti - one of the
most widespread mosquito species globally - the potential
for major and possibly concurrent epidemics of these
viruses and other as yet unknown mosquito-borne viruses
that might emerge, is overwhelming, and emphasizes the
pressing need to develop vaccines and antiviral therapeu-
tics [5]. Moreover, diagnostic tools to reliably distinguish
between the various viral infections that often lead to
similar clinical symptoms [8], but necessitate distinct
management, are urgently required. Dengue is considered
the currently most important arboviral disease [3], with
an estimated 390 million cases annually [9]. Infections
are caused by one of at least four antigenically distinct
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serotypes (DENV1-4) that vary by ~25 to 40 % at the
amino acid level [10]. It has been reported that secondary
infection with a heterologous serotype is associated with
an increased relative risk of severe disease [10, 11]. Ad-
equate management of severe dengue cases can greatly re-
duce the death rate. To date, diagnosis of the infecting
serotype is of epidemiological interest, and in the future
could potentially be relevant for prognosis in individual
patients. Moreover, the canonical DENV serotypes appear
to be antigenically more diverse than previously assumed,
requiring more detailed studies of the relevance of individ-
ual antigenic determinants for clinical severity, epidemic
magnitude, and DENV evolution [12].
Ever since the development of the B cell hybridoma
technology in 1975 [13], the application of monoclonal
antibodies (mAbs) as tools in the development of vaccines,
diagnostics and therapeutics, and as general research tools
has augmented [14–16]. MAbs provide a number of
unique properties including the ability to bind specifically
and with high affinity to almost any molecular structure as
well as their availability in unlimited quantities as homo-
geneous reagents. Prerequisite for the generation of mAbs
by the B cell hybridoma technology is the immunization
of animals - most commonly mice - with the specific tar-
get antigen. In the case of proteins as target structures,
immunization of mice has traditionally been accomplished
by using recombinantly expressed and purified proteins,
an often time-consuming and tedious endeavor. Due to
their clear advantage in terms of yield and cost, simple
prokaryotic expression systems, particularly Escherichia
coli, or lower eukaryotic hosts, such as yeast, have long
dominated the field of recombinant protein expression
[17]. However, mammalian expression systems that are
capable of providing native protein folding, and natural
posttranslational modifications, have been increasingly
used in the past years to reliably express proteins in their
native conformation [18].
In order to meet the requirements for mAbs against
viral proteins for various public health and research ap-
plications, we evaluated here a fast and highly efficient
strategy of mouse immunization with native viral antigens
using mammalian cells that express the recombinant pro-
teins on their surface. This system is based on the trans-
fection of the human embryonic kidney (HEK) suspension
cell line 293F with a plasmid vector encoding the protein
of interest as fusion protein containing a transmembrane
domain, and thereby enabling the presentation of large
amounts of the chimeric membrane-bound target antigen
on the HEK cell surface in a native conformation to
the immune system of animals immunized with the
transfected cells. The DENV genome encodes for three
structural (C, prM and E) and seven nonstructural (NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins [19].
We have chosen the DENV NS1 protein as recombinant
target antigen in this study, since NS1 is an important bio-
marker for early diagnosis of dengue infections and has
also been intensively investigated as a potential target for
vaccines and antibody-based antiviral therapeutics. De-
pending on its glycosylation status, NS1 has a molecular
weight of 46–55 kDa. The protein exists in multiple
oligomeric forms and occurs as intracellular membrane-
associated form, on the cell surface, or as a soluble, se-
creted lipoparticle [20] that can be detected in the
serum of dengue patients during the acute phase of the
disease [21].
The specific objectives of the present study were i) to
prove the suitability of the applied immunization strategy
for viral proteins, ii) to generate mAbs specifically recog-
nizing the D1NS1 and D4NS1 proteins in their native con-
formation, and iii) to show that these mAbs can be used




Immunization of Naval Medical Research Institute (NMRI)
mice was performed in strict accordance with the rules and
regulations for the protection of animal rights of the Swiss
Federal Food Safety and Veterinary Office. Experiments
were approved by the animal welfare committee of the
Canton of Basel (authorization number 2375).
Construction and amplification of plasmids containing
DENV NS1 protein-encoding sequences
An expression plasmid pcDNA3.1 (Invitrogen, San Diego,
CA) was used that has been modified to supply inserted
genes with the secretion signal sequence of bee venom
mellitin (BVM), a FLAG-tag, a trans-membrane (TM)
domain and a hexa-His tag [22] to enable the expres-
sion of specific proteins on the surface of mammalian
cells transfected with the plasmid. In addition to the
DENV D1NS1 and D4NS1 protein used for immunization
of mice and generation of mAbs, we also expressed the
D2NS1 and D3NS1 proteins for analyses of the DENV
serotype-specificity of the generated mAbs. The D1NS1 -
D4NS1-encoding sequences (amino acid sequences are
provided in Additional file 1: Figure S1), were cloned with
restriction sites NheI and NotI into the modified




TM_HIS plasmids, chemically competent E. coli One Shot
Top10 cells (Invitrogen, San Diego, CA) were transformed
according to the manufacturer’s instructions and grown in
LB medium containing 100 μg/ml ampicillin. DNA was ex-
tracted and purified using the NucleoBond Xtra Maxi Plus
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plasmid DNA purification kit (Macherey-Nagel, Düren,
Germany).
Transfection of HEK 293F cells
The HEK cell line 293F was grown in FreeStyle 293 Ex-
pression Medium (Gibco, Grand Island, NY) in 125 ml
disposable polycarbonate Erlenmeyer flasks (Corning,
Oneonta, NY). Cells were maintained in a humidified in-
cubator at 37 °C in 5 % CO2 on a platform shaker with
rotation at 150 rpm and were passaged when the con-
centration of viable cells reached 2 × 106 cells per ml.
For the transfections, 50 μg of plasmid DNA and 150 μl
of Lipofectamine 2000 Reagent (Invitrogen, Carlsbad,
CA) were diluted each in 2.5 ml FreeStyle medium.
DNA was added to the Lipofectamine Reagent and incu-
bated for 5 min at room temperature. The mix was then
added to 45 ml of HEK cells diluted to 106 cells per ml
and transfected cells were cultured as described above.
After 48 h, transfected cells (D1NS1-HEK - D4NS1-HEK)
were harvested. Levels of NS1 expression were assessed by
Western blot analysis and immunofluorescence assay
(IFA). Aliquots of 6 × 106 transfected HEK cells each were
stored in freezing medium (50 % fetal bovine serum, 40 %
Freestyle medium and 10 % dimethylsulfoxid) in order to
preserve the viability of the transfected cells at −80 °C
until further use.
Generation of mAbs against the D1NS1 and D4NS1
proteins
Stored aliquots of 6 × 106 transfected D1NS1-HEK or
D4NS1-HEK cells were thawed, washed and re-suspended
in 0.9 % sodium chloride. Immunization of NMRI mice
was conducted by intravenous injections of 106 transfected
HEK cells per dose in two cycles of four consecutive days
with a break between cycles of 1 week. Mice with high
anti-DENV NS1 IgG titers as determined by IFA of mouse
sera on transfected and untransfected HEK cells and
by ELISA of mouse sera on recombinant DENV NS1
(recD1NS1 and recD4NS1) proteins (AbD Serotec,
Puchheim, Germany) were selected. The recombinant
D1NS1 (sequence strain Nauru/Western Pacific/1974) and
D4NS1 (sequence strain Dominica/814669/1981) proteins
purchased from AbD Serotec are purified recombinant
proteins expressed in HEK293 cells and presented in
their native folded state with post-translational modifi-
cations. Selected mice received a final boost of 106
transfected HEK cells each on two consecutive days.
Two days after the last injections, selected mice were
sacrificed and their spleens were aseptically removed.
Mouse spleen cells and PAI myeloma cells were fused
to generate antibody-producing hybridoma cell lines as
described [23].
DENV production
DENV serotype 1 (strain Hawaii), DENV serotype 3
(strain H87), and DENV serotype 4 (strain H241) virus
stocks were prepared by virus amplification in VeroE6
cells. Virus stock titers were determined by plaque assay.
In brief, VeroE6 cells were infected with serial dilutions
of virus supernatants. Two hours post-infection the in-
oculum was replaced by serum-free MEM medium (Life
Technologies, Darmstadt, Germany) containing 1.5 %
carboxymethyl cellulose (Sigma-Aldrich, Taufkirchen,
Germany). Five days post-infection, cells were fixed by
addition of formaldehyde to a final concentration of 5 %.
Cells were stained with crystal violet solution (1 % crys-
tal violet, 10 % ethanol in H2O) for 30 min at room
temperature and rinsed extensively with H2O. Infectious
titers were calculated considering the corresponding di-
lution factor. DENV serotype 2 (strain New Guinea C)
virus stock was produced by electroporation of BHK-21
cells with in vitro transcripts and further amplification
of the BHK-21 supernatant in VeroE6 cells as described
above. Virus stock titer was determined by plaque assay
and cells were fixed 7 days post infection.
Western blot analysis with HEK cell and VeroE6 cell
lysates
In order to prepare HEK cell protein lysates, aliquots of
6 × 106 transfected or untransfected (negative control)
HEK cells were thawed, washed and re-suspended in
600 μl of RIPA buffer containing 20 mM Tris HCl,
137 mM NaCl, 10 % glycerol, 1 % NP-40, 0.25 % sodium
deoxycholate and a protease inhibitor cocktail (cOmplete
Mini; Roche, Mannheim, Germany). After incubation for
30 min on ice, the mix was centrifuged at 10’000 rpm for
10 min and the supernatant was stored at −20 °C.
For VeroE6 cell lysates, 106 cells were infected with a
multiplicity of infection of 10 for 36 h (DENV serotypes
1, 2 and 4) and 48 h (DENV serotype 3). Cells were lysed
with 100 μl ice-cold lysis buffer (50 mM Tris HCl
pH 7.4, 150 mM NaCl, 1 % Triton X-100, 60 mM β-glyc-
erophosphate, 15 mM 4-nitrophenylphosphate, 1 mM so-
dium orthovanadate, 1 mM sodium fluoride, and
protease inhibitor cocktail).
For SDS-PAGE, 2 μg of HEK cell lysates per lane were
separated on NuPAGE Novex 4–12 % Bis-Tris Gels
(Invitrogen, Carlsbad, CA) with addition of NuPage Re-
ducing Agent (Invitrogen, Carlsbad, CA) and heating of
the samples for 5 min at 95 °C (reducing conditions). Ly-
sates of DENV-infected VeroE6 cells were separated on
NuPAGE Novex 4–12 % Bis-Tris Zoom Gels under non-
reducing conditions (without addition of reducing agent
and without heating of samples). After electrophoresis,
protein bands were either visualized directly with aqua-
staining or were transferred onto nitrocellulose membranes
for Western blot analysis using an iBlot Gel Transfer
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Device (Invitrogen). Membranes were blocked with 5 %
non-fat dry milk in PBS containing 0.1 % Tween 20 and
cut into strips, if required. Membranes or membrane
strips were then incubated with anti-hexa-His tag, anti-
tubulin or anti-DENV NS1 mAbs, washed with PBS con-
taining 0.1 % Tween 20 and thereafter incubated with
horseradish peroxidase-conjugated goat anti-mouse IgG
antibodies (γ-chain specific; Southern Biotech, Birmingham,
AL). After a second washing step, bands were visualized by
chemiluminescence using ECL Western Blotting substrate
(Thermo Scientific, Rockford, IL).
Immunofluorescence staining of HEK cells
For IFA, an aliquot of 6 × 106 transfected HEK cells was
thawed, washed and re-suspended in 600 μl of PBS. Each
well of 12-well multi-test glass slides (MP Biomedicals,
Inc., Illkirch, France) was coated with 2 μl of the cell
suspension. After air-drying under a sterile hood, cells
were fixed in methanol for 15 min. Dried wells were
then incubated with either hybridoma cell culture super-
natant or purified mAbs diluted in PBS containing 0.5 %
BSA for 20 min in a wet chamber at 37 °C. Following
rinsing, washing twice for 5 min in PBS containing 0.05 %
Tween 20 and rinsing in distilled H2O, dried wells were
incubated with Alexa568-conjugated goat anti-mouse IgG
antibodies (KPL, Gaithersburg, MD) diluted in PBS con-
taining 0.5 % BSA for 20 min in a wet chamber at 37 °C.
After washing as described, dried slides were mounted
with ProLong Gold antifade reagent with DAPI (Life
technologies, Eugene, OR) and covered with a cover
slip. Analyses were performed on a Leica CTR500
fluorescence microscope and images were taken with a
Leica DFC345 FX digital camera (Leica Microsystems,
Heerbrugg, Switzerland).
Conventional ELISA on recombinant NS1 proteins
96-well Nunc-Immuno Maxisorp plates (Thermo Scien-
tific, Roskilde, Denmark) were coated overnight at 4 °C
in a wet chamber with 50 μl PBS containing recombin-
ant DENV NS1 (recD1NS1 and recD4NS1) protein
(AbD Serotec, Puchheim, Germany) at a concentration
of 1 μg/ml or an unrelated hexa-His tagged protein
(MUL_3720 [24]) serving as a control. After washing
with distilled H2O containing 0.01 % Tween 20, wells
were blocked with 5 % non-fat dry milk in PBS for 1 h
at 37 °C. Subsequently, wells were incubated with mouse
antisera or hybridoma cell culture supernatant diluted
in PBS containing 0.5 % milk and 0.05 % Tween20 for
1 h at 37 °C. After washing as described, horseradish
peroxidase-conjugated goat anti-mouse IgG antibodies
(γ-chain specific; Southern Biotech, Birmingham, AL)
in PBS containing 0.5 % milk and 0.05 % Tween20 were
incubated for 1 h at 37 °C. Plates were washed and devel-
oped with TMB Microwell Peroxidase Substrate (KPL,
Gaithersburg, MD). The reaction was stopped using 0.5 M
sulfuric acid. The absorbance was measured at 450 nm in
a microplate reader (Tecan Sunrise, Grödig, Austria).
Anti-hexa-His tag capture ELISA
96-well Nunc-Immuno Maxisorp plates (Thermo Scien-
tific, Roskilde, Denmark) were coated overnight at 4 °C in
a wet chamber with 50 μl PBS containing anti-hexa-His
tag antibodies at a concentration of 5 μg/ml. All following
steps were carried out on the next day and at room
temperature. After washing with distilled H2O containing
0.01 % Tween 20, wells were blocked with 5 % non-fat dry
milk in PBS for 2 h. Subsequently, wells were incubated
with D1NS1-HEK - D4NS1-HEK cell whole protein ly-
sates diluted in PBS for 2 h. After another washing step,
wells were incubated with biotinylated anti-NS1 mAbs at
a concentration of 5 μg/ml diluted in PBS containing
0.5 % milk for 2 h. Wells were washed and incubated with
horseradish peroxidase-conjugated Streptavidin in PBS
containing 0.5 % milk for 1 h. Plates were washed and de-
veloped with TMB Microwell Peroxidase Substrate (KPL,
Gaithersburg, MD). The reaction was stopped using 0.5 M
sulfuric acid. The absorbance was measured at 450 nm in
a microplate reader (Tecan Sunrise, Grödig, Austria).
Commercial DENV NS1 capture ELISA
Lysates of VeroE6 cells infected with different DENV se-
rotypes were analyzed for their NS1 content by a DENV
NS1-specific capture ELISA (EUROIMMUN, Luzern,
Switzerland) according to the manufacturer’s instruc-
tions. The three calibrator samples supplied with the kit
were applied to assess relative units of the NS1 protein
present in the samples.
Results
Expression of D1NS1 and D4NS1 on the surface of
transfected HEK 293F cells
After transfection of HEK cells with the NS1 fusion
protein-encoding plasmids pcDNA3.1_BVM_D1NS1_
FLAG_TM_HIS or pcDNA3.1_BVM_D4NS1_FLAG_
TM_HIS, the expression of D1NS1 and D4NS1 by the
transfectants was analyzed. No elevated expression
levels of a protein corresponding in size to the NS1 pro-
tein was visible upon aqua-staining of the SDS-PAGE sep-
arated total proteins of D1NS1-HEK and D4NS1-HEK cell
lysates when compared to a lysate of untransfected HEK
cells (Fig. 1a). However, Western blot analysis with anti-
hexa-His tag antibodies (Fig. 1b) confirmed the specific
expression of the NS1 fusion proteins (a band at the
expected size for the monomer NS1 of 46–55 kDa [20])
by the transfectants. In combination with Western blot
analysis with anti-tubulin antibodies serving as a loading
control (Fig. 1c), these analyses revealed no significant dif-
ference between expression levels of D1NS1 and D4NS1.
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IFA of D1NS1-HEK, D4NS1-HEK and untransfected HEK
cells with anti-hexa-His tag antibodies demonstrated the
cell surface localization of the expressed NS1 fusion
proteins with similar staining intensities for D1NS1 and
D4NS1 (Fig. 2).
Development of DENV NS1-specific antibody responses in
mice by immunization with transfected HEK cells
Immunization of mice with either D1NS1-HEK or
D4NS1-HEK cells resulted in the development of humoral
immune responses specific for the NS1 proteins (Fig. 3).
Sera of mice immunized with D1NS1-HEK contained
higher titers of antibodies against recD1NS1 (Fig. 3a) than
against recD4NS1 (Fig. 3c). In contrast, similar antibody
titers to both recD1NS1 and recD4NS1 were detected in
mice that were immunized with D4NS1-HEK cells (Fig. 3b
and d). Individual mouse antisera of the D1NS1-HEK and
D4NS1-HEK mouse groups contained similar levels of
antibodies to the NS1 target protein. All mouse antisera
showed only very low anti-hexa-His tag antibody levels, as
determined by ELISA of the sera on an unrelated hexa-
His tagged protein (MUL_3720) (Fig. 3e and f).
Fig. 1 Expression of D1NS1 and D4NS1 by transfected HEK cells. HEK cell lysates were analyzed by aqua-staining and Western blot analysis after
separation on NuPAGE Novex 4–12 % Bis-Tris Gels under reducing conditions (addition of reducing agent and heating of the samples). While
aqua-staining of lysates prepared from HEK-derived cell lines expressing D1NS1 (D1) and D4NS1 (D4) showed no additional band of the predicted
size of the NS1 proteins, as compared to the lysates of untransfected HEK cells (−) (a), Western blot analysis using anti-hexa-His tag antibodies
confirmed the expression of D1NS1 and D4NS1 by the HEK cells (b). Western blotting using anti-tubulin antibodies was performed as a control
for the amount of cellular proteins of the untransfected and transfected HEK cell lysates loaded on the gels (c). M =molecular weight marker
in kDa
Fig. 2 Localization of D1NS1 and D4NS1 on the surface of transfected HEK cells. IFA of methanol fixed D1NS1-HEK, D4NS1-HEK and untransfected
HEK cells using mouse anti-hexa-His tag mAbs and Alexa568-labelled anti-mouse IgG antibodies. Nuclei were stained with DAPI
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Fig. 3 ELISAs showing humoral immune responses of mice immunized with D1NS1-HEK and D4NS1-HEK cells. a and b: Mouse antisera of D1NS1-HEK
(red, panel a) and D4NS1-HEK (blue, panel b) immunized mouse groups (4 mice each) were analyzed on recombinant D1NS1 and recombinant D4NS1,
respectively. c and d: Serotype cross-reactive humoral immune responses of D1NS1-HEK (red, panel c) and D4NS1-HEK (blue, panel d) mouse groups
were analyzed on recombinant D4NS1 and recombinant D1NS1, respectively. Blue line (panel c) and red line (panel d) = pool of D4NS1-HEK and
D1NS1-HEK mouse antisera, respectively, to enable direct comparison with the level of serotype-specific immune responses. e and f: Analysis of pooled
mouse sera (red = D1NS1-HEK (e), blue = D4NS1-HEK (f)) on an unrelated hexa-His tagged protein (MUL_3720) as a control for humoral responses
against the hexa-His tag. Black line in all panels = pool of mouse sera before immunization (pre-bleed)
Table 1 Characteristics and reactivities of the generated anti-NS1 mAbs
IFA ELISA Western blot analysis
Transfected HEK cells Transfected HEK cell lysates DENV-infected Vero E6 cell lysates
mAb Isotype D1 D4 D1 D2 D3 D4 D1 D2 D3 D4
NR1.1 IgG1, κ + - + - - - + - - -
NR1.2 IgG1, κ + - + - - - + - + -
NR1.3 IgG1, κ + - + - - - + - - -
NR1.4 IgG2a, κ + + + + + - + + + -
NR1.5 IgG2a, κ + + + - - + + - - -
NR1.6 IgG1, κ + - + - - - + - - -
NR1.7 IgG2a, κ + - + - - - + - - -
NR1.8 IgG2b, κ + + + - + + + + + +
NR4.1 IgG2a, κ - + - - - + - - - +
NR4.2 IgG2a, κ - + - - - + - - - +
NR4.3 IgG1, κ + + - - - + - - - +
NR4.4 IgG2a, κ - + - - - + - - - +
The different recognition patterns of the 12 generated anti-NS1 mAbs as determined by i) IFA on the D1NS1 and D4NS1 transfected HEK cells, ii) ELISA on whole
protein lysates of D1NS1-HEK - D4NS1-HEK cells and iii) Western blot analysis on whole protein lysates of DENV-infected VeroE6 cells are summarized
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Generation and characterization of anti-DENV NS1 mAbs
Fusion of spleen cells obtained from mice immunized
with D1NS1-HEK or D4NS1-HEK cells with PAI mye-
loma cells enabled the generation of anti-NS1 antibody-
producing hybridoma cell lines. In order to identify cell
lines that produce IgG specific for NS1, hybridoma su-
pernatants were screened by ELISA on recD1NS1 or
recD4NS1, respectively. Supernatants from ELISA-positive
wells were subsequently tested by IFA on D1NS1-HEK and
D4NS1-HEK cells. IFA on HEK cells transfected with
an unrelated hexa-His tagged protein served as control
to identify those hybridoma cell lines that generated
NS1-specific antibodies. Screening of D1NS1-HEK and
D4NS1-HEK mouse spleen cell fusions yielded eight
and four anti-DENV NS1 IgG-producing hybridoma
cell lines, respectively. These cell lines were cloned by
limiting dilution to obtain hybridoma clones producing
the mAbs NR1.1 - NR1.8 and NR4.1 - NR4.4, respectively.
Five mAbs were of the IgG1(κ), six of the IgG2a(κ) and
one of the IgG2b(κ) IgG subclass (Table 1). IFA with these
mAbs on the D1NS1 and D4NS1 transfectants revealed
that five specifically recognized D1NS1-HEK but not
D4NS1-HEK cells, three only reacted with D4NS1-HEK
cells and the remaining four were cross-reactive with both
transfectants (Table 1, Fig. 4).
In order to test serotype-specificity of the generated
mAbs on all four DENV serotypes, analyses were ex-
tended to HEK cells expressing D2NS1 and D3NS1
(Additional file 2: Figure S2). When serotype specificity
was tested by ELISA using anti-hexa-His tag antibodies
as common capturing reagent for all four hexa-His
tagged NS1 fusion proteins from HEK cell lysates, differ-
ent recognition patterns were observed for the 12 anti-
NS1 mAbs used as biotinylated detecting reagents in
ELISA. While five of the eight mAbs raised against
D1NS1 (NR1.1, NR1.2, NR1.3, NR1.6 and NR1.7) specific-
ally recognized only D1NS1, three (NR1.4, NR1.5 and
NR1.8) also cross-reacted with the NS1 protein of at least
one other serotype. In contrast, all four mAbs raised
against D4NS1 (NR4.1 – NR4.4) reacted only with D4NS1
in ELISA (Table 1, Fig. 5).
Detection of virus material derived from DENV-infected
VeroE6 cells by the generated mAbs
Cross-reactivity of the generated mAbs with virus-
infected cells was analyzed by Western blot analysis with
lysates of VeroE6 cells infected with the four different
DENV serotypes (Fig. 6). Results were nearly identical to
the ELISA analysis of all four hexa-His tagged NS1 fu-
sion proteins from HEK cell lysates with three excep-
tions: i) the Western blot cross-reactive mAb NR1.8 did
not react with the D2NS1 protein in the ELISA, ii) mAb
NR1.2 did recognize D3NS1 in virus material, but not
the NS1 protein present in D3NS1-HEK cell lysates and
iii) mAb NR1.5 recognized NS1 in D4NS1-HEK cell ly-
sates, but not the one present in the virus-infected cell
lysates. Analysis with lysates of the virus-infected cells
showed that mAb NR1.8 is cross-reactive with all four
DENV serotypes. Five of the mAbs specifically reacted
Fig. 4 IFA of selected generated anti-NS1 mAbs on HEK cells. IFA of
methanol fixed D1NS1-HEK, D4NS1-HEK and untransfected HEK cells
after staining with selected generated anti-NS1 mAbs and Alexa568-
labelled anti-mouse IgG antibodies. a: D1NS1 and D4NS1 serotype
cross-reactive mAb NR1.8. b: D1NS1 serotype-specific mAb NR1.1.
c: D4NS1 serotype-specific mAb NR4.4. Nuclei were stained with DAPI
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with D1NS1 and four recognized D4NS1 only. One of
the mAbs cross-reacted with D1NS1 - D3NS1, but did
not recognize D4NS1 and one reacted with D1NS1 and
D3NS1 (Fig. 6, Table 1).
Discussion
In the present study, we describe an efficient and cost-
effective strategy to rapidly generate mouse mAbs
against native viral proteins. The methodology used is
based on the immunization of mice with HEK cells pre-
senting the native target proteins on their surface. Ex-
pression of the proteins on the HEK cell surface is
achieved by hijacking the HEK cell’s synthetic protein
machinery upon transfection of the cells with a plasmid
encoding the target antigen as fusion protein connected
to a transmembrane domain [22]. The use of HEK cells
as a tool for the expression of native proteins has several
advantages. For one, HEK cells are easy to grow in cul-
ture, can efficiently be transfected with commercially
available transfection reagents, and are also capable of
expressing large amounts of recombinant proteins [25].
Moreover, mammalian cell cultures - as opposed to pro-
karyotic or yeast expression systems – represent an optimal
tool for the production of viral proteins (particularly glyco-
proteins [26]), since protein folding and post-translational
modifications closely approximate those occurring in the
infected mammalian hosts [27]. The immunization of mice
with antigens hooked to the surface of HEK cells has the
further advantages that neither elaborate production/
processing of recombinant antigen nor addition of ad-
juvant - that both may negatively affect protein folding -
are required.
Here we used this novel approach to rapidly gener-
ate panels of mAbs against the DENV NS1 protein.
Fig. 5 ELISAs of D1NS1-HEK - D4NS1-HEK cell whole protein lysates with the generated mAbs. DENV NS1 serotype-specificity of the 12 generated
mAbs was assessed by capturing the NS1 protein in D1NS1 - D4NS1 HEK cell lysates using anti-hexa-His tag mAbs and detecting the protein with
the anti-NS1 mAbs NR1.1 - NR1.8 and NR4.1 - NR4.4. a: While analyses with mAbs NR1.1 - NR1.3, NR1.6 and NR1.7 exhibited a high degree of
D1NS1-specificity in the ELISA, mAbs NR1.4, NR1.5 and NR1.8 showed a certain degree of NS1 cross-reactivity among different DENV serotypes.
b: MAbs NR4.1 - NR4.4 were highly specific for D4NS1, since they did not recognize D1NS1 - D3NS1 in the HEK cell lysates. M = molecular
weight marker in kDa
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Immunization of mice with D1NS1-HEK and D4NS1-
HEK cells, whose viability was preserved by storage at
−80 °C in freezing medium, and subsequent produc-
tion of hybridoma clones yielded D1NS1- and D4NS1
serotype-specific as well as DENV NS1 serotype cross-
reactive mAbs. In view of the 30 % variability present
among sequences of the four DENV serotypes at the
amino acid level (Additional file 1: Figure S1), it was
expected that mice immunized with one serotype will
develop both serotype-specific and serotype cross-
reactive humoral immune responses. In this study a
first selection of the desired mAbs was achieved by
high-throughput ELISA screening of the hybridoma
cell supernatants on small amounts of commercially
available DENV D1NS1 - D4NS1 recombinant proteins.
However, in order to completely circumvent the use of re-
combinant proteins, lower throughput screening can also
be performed by IFA on HEK cells transfected with the
target protein or by Western blot analysis on lysates of
transfected HEK cells. These assays should be performed
in parallel with tests using material from HEK cells trans-
fected with an unrelated hexa-His tagged fusion protein to
exclude hybridomas producing HEK cell and hexa-His
tag –specific antibodies from further analysis. Seven of
the identified mAbs (the D1NS1-specific NR1.1, NR1.3,
NR1.6 and NR1.7 and the D4NS1-specific NR4.1,
NR4.2 and NR4.4) were serotype-specific in all applied
assay formats, while one mAb (NR1.8) reacted with the
NS1 protein of each of the four serotypes in all but one
(ELISA on D2NS1) of the assays. The other four mAbs
(NR1.2, NR1.4, NR1.5 and NR4.3) reacted with the NS1
protein of at least two, but not all of the four DENV se-
rotypes (Table 1). Discrepancies in recognition patterns
might be explained by steric differences (hindrances) in
binding of the mAbs in different assay formats. West-
ern blot analysis of DENV-infected cell lysates con-
firmed that the generated mAbs can be used to detect
the endogenous NS1 protein in DENV-infected bio-
logical samples. Differences in recognition patterns
might also be explained by sub-serotype specificity of
the generated mAbs.
The progressive and ubiquitous threat of newly emer-
ging and re-emerging viral diseases necessitates the devel-
opment of tools for their prevention, detection and
control. In the past decades mAbs have been increasingly
used for the development of vaccines, diagnostics and
therapeutics as well as for research on the epidemiology of
pathogens. In this study we were able to prove our ap-
proach of rapidly generating panels of mAbs against native
viral proteins. The envisaged production of serotype and
sub-serotype variant specific anti-NS1 mAbs against all
DENV serotypes will provide various prospects for their
application. Antigen capture assays for diagnostic pur-
poses may be developed by using a broadly cross-reactive
Fig. 6 ELISA and Western blot analysis of lysates derived from DENV-infected VeroE6 cell lines. a: NS1 relative units were determined in lysates of
VeroE6 cells infected with DENV serotypes 1–4 by NS1 capture ELISA (EUROIMMUN, Luzern, Switzerland). NS1 relative units were calculated in
accordance with the manufacturer’s instructions and approximate values are shown. Gels for Western blot analysis were loaded with DENV
serotype 1–4 infected VeroE6 cell lysates containing 40.000 relative units of NS1, each under non-reducing conditions. The 12 generated mAbs
were tested on serotype 1 (b), serotype 2 (c), serotype 3 (d) and serotype 4 (e) virus-infected cell lysates
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capturing mAb in combination with different serotype-
specific detection mAbs. Variant specific mAbs may be
used as tools to study the epidemiology of DENV isolates
based on their antigenic diversity [12].
Conclusions
Our cell-based system of immunizing mice with HEK
cells presenting native viral proteins followed by hybrid-
oma selection provides a highly efficient tool to rapidly
obtain mAbs against native viral proteins that can be
used for various downstream applications. The strategy can
easily be extended to a broad range of viral proteins.
Additional files
Additional file 1: Figure S1. Dengue virus NS1 protein sequences.
Sequence alignment of the D1NS1 - D4NS1 protein sequences expressed
by the transfected HEK cells showing 30 % sequence variability. Identical
amino acid positions among the four serotypes are highlighted in grey.
(TIF 2689 kb)
Additional file 2: Figure S2. Expression of D2NS1 and D3NS1 by
transfected HEK cells. While aqua staining of lysates prepared from
HEK-derived cell lines expressing D2NS1 (D2) and D3NS1 (D3) showed
no specific band for the NS1 protein as compared to the lysates of
untransfected HEK cells (−) (a), Western blot analysis using anti-hexa-His tag
antibodies confirmed the expression of D2NS1 and D3NS1 by the HEK cells
(b). Western blotting using anti-tubulin antibodies was performed as a
control for the amount of untransfected and transfected HEK cell lysates
loaded on the gels (c). M =molecular weight marker in kDa. (TIF 3371 kb)
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